HK-listed stocks related to theme of minimally-invasive medical treatment rallied across the board this morning (14th), with MICROPORT NEURO (02172.HK)  +0.280 (+2.188%)    Short selling $6.28M; Ratio 3.241%   posting the strongest gains. The stock opened 6.43% higher, peaking at HKD13.78, and last stood at HKD13.14, up 20.77%. Trading volume reached 17.617 million shares, with a turnover of HKD228 million.

MICROPORT (00853.HK)  -0.010 (-0.116%)    Short selling $14.22M; Ratio 8.187%   opened 1.16% higher, hitting a high of HKD9.09. It last traded at HKD8.81, up 13.68%, with a volume of 36.8411 million shares and a turnover of HKD319 million.

MEDBOT-B (02252.HK)  +0.050 (+0.249%)    Short selling $6.00M; Ratio 4.256%   opened 0.49% higher, reaching a high of HKD21.6. It last posted at HKD20.75, up 2.22%, with 4.31 million shares traded and a turnover of HKD90.1034 million.

CARDIOFLOW-B (02160.HK)  +0.010 (+0.909%)   opened 1.82% lower, dipping to a low of HKD1.08. It has since recovered to HKD1.13, up 2.73%, with a trading volume of 1.965 million shares and a turnover of HKD2.2056 million.

A recent JP Morgan report highlighted robust order trend of MEDBOT, noting its significance as a key subsidiary of MICROPORT. The broker expected the subsidiary’s contribution to group sales to rise from about 3% in 2024 to approximately 40% by 2033, on the ride of rapid robot installations in China and overseas markets.

JP Morgan reiterated its positive outlook on MICROPORT, describing it as a diversified local leader in the small- and mid-cap (SMID) medtech sector, with strong innovation capabilities and overseas expansion potential. The broker projected a return to profitability by 2026 and continued to view MICROPORT as its top pick in the SMID medtech space.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-03-17 16:25.)